The Relative Strength (RS) Rating for Ascendis Pharma ADR jumped into a new percentile Friday, with an increase from 75 to 87.
IBD's unique rating identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of above 80 as they begin their biggest climbs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Ascendis Pharma ADR is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could launch a new move.
Ascendis Pharma ADR showed 0% EPS growth last quarter. Sales gains came in at 18%.
The company holds the No. 26 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
